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INTRODUCTION
DNA methylation plays an essential role in the normal
development and in the maintenance of genomic stability
(1-3). However, alterations in methylation patterns frequen-
tly occur in tumor cells, and hypermethylation in the pro-
moter regions of tumor suppressor genes are commonly asso-
ciated with epigenetically mediated gene silencing in human
cancer (4, 5).
The p16INK4a tumor suppressor gene encodes for a cyclin-
dependent kinase inhibitor that is important for cell cycle
progression, and the promoter hypermethylation of this gene
is a frequent occurrence in human solid tumors (6).
In lung cancer, the p16INK4a gene hypermethylation has
been detected in 17% (7) to 84% (8) of cases in different
studies. This is most likely due to the various technical pro-
cedures used (9). Various methods of DNA methylation de-
tection have been used, and these generally rely on a methy-
lation-dependent modification of the original genomic DNA
before any amplification step.
The aims of the present study were to evaluate the methy-
lation status of the promoter region of p16INK4a in lung can-
cer tissue, and to analyze the relationships between methy-
lation status and various clinicopathological parameters using
a real-time quantitative polymerase chain reaction (PCR)
protocol, which is a modified method of the previous devel-
oped PCR technique (10).
MATERIALS AND METHODS
Study population
The study subjects were recruited from patients admitted
to the Department of Thoracic and Cardiovascular Surgery
at Dong-A University Hospital in Busan, Korea from March
2006 to January 2007. Tumor specimens were collected from
a series of 81 non-small cell lung cancers (NSCLCs). The
study design was approved by the Committee on Human
Research of Dong-A University Hospital. The study subjects
gave informed consent prior to participation in the study. 
DNA extraction
Immediately after surgical resection, tumor specimens and
adjacent normal specimens were collected by a pathologist
and stored at -80℃. DNA samples (10-20 mg) were obtain-
ed from tumor and non-tumorous tissue samples using Wiz-
ard genomic DNA purification kits (Promega, Madison,
U.S.A.), according to the manufacturer’s instructions. 
p16
INK4a hypermethylation analysis
Real-Time PCR (ABI PRISM 7000 Sequence Detection
System, Applied Biosystems, Faster City, U.S.A.) was used
to quantify genomic target sequences using SYBR Green 2X
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Hypermethylation of p16
INK4a in Korean Non-small Cell Lung Cancer
Patients
Promoter hypermethylation of the p16
INK4a gene was investigated in 81 sets of sam-
ples of tumor tissue and adjacent normal tissue from Korean patients with primary
lung cancer, using the modified real-time polymerase chain reaction (PCR)/ SYBR
Green detection method. The results showed hypermethylation of p16
INK4a in 27.2%
of tumor tissues, and in 11.1% of adjacent normal tissue. No significant associa-
tion was found between the overall aberrant methylation in tumor and correspond-
ing normal specimens (r=0.137, p=0.219). In 22 cases with p16
INK4a hypermethyla-
tion in tumor tissues, only 4 (18.1%) cases were found to have a hypermethylated
normal tissue specimen. The findings of this study show that smoking can influ-
ence the methylation level of the promoter region of p16
INK4a, and that this occurs in
tumor tissues more frequently than in normal tissues. Other clinicopathological char-
acteristics, including age, sex, tumor stage, and histologic type were not found to
be correlated with p16
INK4a methylation.
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PCR Master Mix (Applied Biosystems) for detection. The
p16INK4a gene methylation status was determined by real-time
methylation specific PCR followed by restriction enzyme
digestion.
One microgram of genomic DNA was incubated for 7 days
at 37℃ with Msp I and Hpa II (New England BioLab, Bev-
erly, MA, U.S.A.). When the external C in the sequence CC-
GG of p16INK4a is methylated, Msp I and Hpa II cannot cleave
p16INK4a. However, unlike Hpa I, Msp II can cleave this sequ-
ence when the internal C residue is methylated.
Each PCR reaction mixture contained genomic DNA, 5
pM of primers, and SYBR green 2X PCR master mix (App-
lied Biosystems) in a final volume of 20  L. The primer se-
quences and target sites are shown in the Fig. 1 and Table 1.
The standard amplification protocol consisted of an initial
denaturation step for 10 min at 95℃, followed by 35 ampli-
fication cycles at 94℃ for 15 sec, each annealing tempera-
ture (67, 68 and 69℃) for 30 sec and 72℃ for 30 sec (Fig.
2 and Table 1). A standard curve was established with a 10-
fold dilution series of DNA ranging from 1×100 to 1×103
ng. The DNA sample used for the standard curve was wi-38
at a known concentration (814 ng/ L) (Fig. 3). After PCR,
each amplification reaction was checked using a dissociation
curve.
Calculation of methylation 
Raw data were analyzed using the ABI 7000 System Soft-
ware. The methylation status in each sample was expressed
as a threshold cycle (CT) ratio. The CT is the fractional cycle
number at which the fluorescence signal reaches an arbitrary
but defined threshold value within the early exponential phase
of the reaction. CT values are proportional to the logarithm
of the initial copy numbers of the target and are used to deter-
mine the initial copy numbers of samples. The CT ratio ref-
lects methylation and was calculated as follows: CT ratio=(CT
of target gene without tratment-CT of a target gene treated
with Hpa II)/(CT of target gene without treatment-CT of a
target gene treated with Msp I), The values of the CT ratio
are between 0 and 1. In a totally non-methylated state, the
CTratio of the p16INK4a gene is 1; thus, a lower CTratio reflects
-492 ACGCACTCAA ACACGCCTTT GCTGGCAGGC GGGGGAGCGC GGCTGGGAGC AGGGAGGCCG
-432 GAGGGCGGTG TGGGGGGCAG GTGGGGAGGA GCCCAGTCCT CCTTCCTTGC CAACGCTGGC
-372 TCTGGCGAGG GCTGCTTCCG GCTGGTGCCC CCGGGGGAGA CCCAACCTGG GGCGACTTCA
-312 GGGGTGCCAC ATTCGCTAAG TGCTCGGAGT TAATAGCACC TCCTCCGAGC ACTCGCTCAC
-252 AGCGTCCCCT TGCCTGGAAA GATACCGCGG TCCCTCCAGA GGATTTGAGG GACAGGGTCG
-192 GAGGGGGCTC TTCCGCCAGC ACCGGAGGAA GAAAGAGGAG GGGCTGGCTG GTCACCAGAG
-132 GGTGGGGCGG ACCGAGTGCG CTCGGCGGCT GCGGAGAGGG GTAGAGCAGG CAGCGGGCGG
-72 CGGGGAGCAG CATGGAGCCG GCGGCGGGGA GCAGCATGGA GCCTTCGGCT GACTGGCTGG
-12 CCACGGCCGC GG
Fig. 1. Methylation analysis
of the p16
INK4a promoter se-
quencing (Genebank ac-
cession number X94154).
The positions of the CCGG
sites are underlined. Each
primer is shown in bold cha-
racters. 
Site Primer sequences (5′ →3′ )
Annealing 
tempe-
rature (°C)
p16
INK4a-1 Forward: 5′ -ACGCCTTTGCTGGCAGGCGGG-3′ 68
Reverse: 5′ -CGCCAGAGCCAGCGTTGGCAAG-3′
p16
INK4a-2 Forward: 5′ -CTTGCCAACGCTGGCTCTGGCG-3′ 69
Reverse: 5′ -CCTCTGGAGGGACCGCGGTATC-3′
p16
INK4a-3 Forward:5′ -GATACCGCGGTCCCTCCAGAGG -3′ 67
Reverse: 5′ -CTCCGCAGCCGCCGAGCGCACT-3′
p16
INK4a-4 Forward: 5′ -AGTGCGCTCGGCGGCTGCGGAG-3′67
Reverse: 5′ -GCCAGTCAGCCGAAGGCTCCATG-3′
Table 1. Primer sequences and annealing temperature for PCR
reactions for promoter regions of the p16
INK4a gene
Fig. 2. Results of p16
INK4a gene promoter methylation of normal (A) and tumor (B) lung tissues by real-time PCR. 2, 3, 5: Normal lung tissues
(A); 2*, 3*, 5*: tumor lung tissues (B); 1, 4, 6: positive control (wi-38); 7: negative control (water); a: no-cut DNA amplification; b: Hpa II-cut
DNA amplification; c: Msp I-cut DNA amplification. Delta Rn: the magnitude of the fluorescence signal generated during the PCR at each
time point. 
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a higher level of methylation. 
Human cell line wi-38 (KCLB No. 10075.1, epithelium,
lung) was used as a positive control for methylated alleles.
Water blanks were used as negative controls. 
Statistical analyses
The association between the p16INK4a hypermethylation
and clinicopathological parameters was analyzed using con-
tingency tables. Statistical significance was evaluated using
the  2-test. The variables on the association analyses includ-
ed: age, sex, histological subgroup, stage, smoking status,
and tobacco consumption. Data on smoking habits were ob-
tained by an interview. The difference was considered to be
statistically significant if the pvalue was <0.05. The data were
analyzed using the Statistical Package Service Solution soft-
ware (SPSS version 12.0, Chicago, IL, U.S.A.).
RESULTS 
p16
INK4a Methylation in primary NSCLC
In order to examine the methylation status of the p16INK4a
promoter region, samples of tumor and normal adjacent tis-
sues from 81 primary lung cancer patients were analyzed.
Aberrant methylation of p16INK4a was detected in samples
derived from squamous cell carcinoma (SCC), adenocarcino-
ma (ADC), large cell carcinoma (LCC), and bronchoalveolar
carcinoma (BAC), but not from small cell lung cancer (SCLC).
Among these, the frequencies for hypermethylation of
p16INK4a were 27.2% in tumor tissue and 11.1% in adjacent
normal specimens. Hypermethylation of p16INK4a was more
frequently identified in tumor tissues than in normal tissues
with a statistical significance (p=0.009). No significant asso-
ciation was found between the overall aberrant methylation
in tumors and the corresponding normal specimens (r=0.137,
p=0.219). In 22 cases with p16INK4a hypermethylation in tu-
mor tissues, only 4 (18.1%) cases were found to have a hyper-
methylated normal tissue specimen (Fig. 4). 
Clinicopathologic and smoking parameters of tumors
with a methylated p16
INK4a gene
The methylation status of the p16INK4a gene was compared
with the clinicopathologic features of each NSCLC tumor
(Table 2). SCC and ADC, which are major histological types
of NSCLC, accounted for 91.4% (74/81) of the 81 cases exam-
ined in this work. In the SCC cases, hypermethylation was
more frequently detected than in ADC cases both in tumor
and in normal adjacent tissues, but the difference was not
significant. Importantly, the incidence of p16INK4a methyla-
tion in tumor specimens was significantly higher in heavy
smokers (>40 pack-years; p=0.045) and was more likely to
be observed in those who had smoked (18/61, 29.5%) than
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Fig. 3. Result of serial dilutions to determine the detection limits of
the real-time PCR protocol showing the initial DNA amounts used
in the amplification. 
Fig. 4. Methylation status of the p16
INK4a gene prompter in normal
and tumor tissues. The black circle denotes methylation positivi-
ty, and the open circle indicates that the sample was negative
for methylation. N, normal tissue; T, tumor tissue.
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in those who had never smoked (4 of 20, 20%), albeit with-
out a statistical significance. Other clinical characteristics,
including age, sex, and tumor stage were not correlated with
p16INK4a methylation.
DISCUSSION
Several studies have described the importance of DNA
methylation in human cancers and have tried to identify
genes that are important for the carcinogenesis process. In
particular, methylation of the p16INK4a tumor suppressor gene
has been studied in various malignancies including lung can-
cer (11-15). 
Using a SYBR Green methylation-specific PCR method,
p16INK4a methylation was detected in 27.2% of lung tumor
tissues. Harden et al. (7) detected methylation of the p16INK4a
gene in 17% of lung cancer patients, and Liu et al. (8) ob-
served p16INK4a gene methylation in 84% of lung cancer pa-
tients. This difference may be attributed to the different
methodologies used for measuring the methylation status.
Moreover, racial differences might also explain the low rate
of p16INK4a hypermethylation observed in lung cancer in
Koreans.
The first generation of methylation detection assays in-
volved the digestion of genomic DNA with a methylation-
sensitive restriction enzyme followed by Southern blot anal-
ysis (16). These methods are relatively straightforward, but
are associated with problems such as the limited availability
of informative restriction sites, false positive results (due to
incomplete digestion), and a requirement for large amounts
of high-molecular-weight DNA. These issues have restricted
the use of these methods (17). The Second-generation tech-
nique resulted from the finding that the treatment of geno-
mic DNA with sodium bisulfite followed by an alkaline
treatment converts unmethylated cytosine to uracil, while
leaving methylated cytosine residues intact (18). Moreover,
methylation detection assays require gel electrophoresis and
many of them employ restriction enzyme digestion, radio-
labeled dNTPs or hybridization probes. These labor-inten-
sive steps have limited the usefulness of these methods.
The strongest feature of the real-time PCR/SYBR Green
detection method is the continuous optical monitoring of
the progress of a fluorescent PCR reaction. Fluorescence inten-
sity increases proportionally to the amount of PCR products.
Therefore, the modified method allows conclusions to be
drawn concerning the methylation status relative to a con-
trol reaction.
n p
Tumor
Methylated (%) Unmethylated (%)
p
Normal (adjacent)
Methylated (%) Unmethylated (%)
Frequency 81 22 (27.2) 59 (72.8) 9 (11.1) 72 (88.9) 0.009
Gender
Male 63 19 (30.2) 44 (69.8) 0.259 7 (11.1) 56 (88.9) 1.00
Female 18 3 (16.7) 15 (83.3) 2 (11.1) 16 (88.9)
Age (yrs)
<50 7 2 (22.2) 6 (77.8) 0.935 0 (0.0) 9 (100.0) 0.506
50-60 22 6 (28.6) 15 (71.4) 3 (14.3) 18 (85.7)
>60 52 14 (26.9) 37 (73.1) 6 (11.7) 45 (88.3)
Histology  
SCC 40 14 (35.0) 26 (65.0) 0.092 6 (15.0) 34 (85.0) 0.434
ADC 34 5 (14.7) 29 (85.3) 3 (8.8) 31 (91.2)
Other* 7 3 4 0 7
Stage
1 39 9 (23.1) 30 (76.9) 0.638 6 (15.4) 33 (84.6) 0.520
2 10 4 (40.0) 6 (60.0) 0 (0.0) 10 (100.0)
3 30 8 (26.7) 22 (73.3) 3 (10.0) 27 (90.0)
4 2 1 (50.0) 1 (50.0) 0 (0.0) 2 (100.0)
Smoking status
Never 20 4 (20.0) 16 (80.0) 0.409 1 (5.0) 19 (95.0) 0.439
Ever 61 18 (29.5) 43 (70.5) 8 (13.1) 53 (86.9) 
Smoker (pack-years) 38.4±22.0 26.4±22.4 0.033 43.9±22.9 27.8±22.1 0.069
Tobacco consumption
0 20 4 (20.0) 16 (80.00) 0.045 1 (5.0) 19 (95.0) 0.449
<20 12 0 (0.0) 10 (100.0) 0 (0.0) 8 (100.0)
20-40 32 7 (25.0) 21 (75.0) 4 (14.3) 24 (85.7) 
>40 17 11(44.0) 14 (56.0) 4 (16.0) 21 (84.0)
Table 2. Promoter methylation of the p16
INK4a gene and clinicopathological characteristics in primary non-small cell lung cancer
*, Other histological types including one SCLC (small-cell lung cancer), three LCLC (large-cell lung cancers), two BAC (bronchoalveolar carcinomas)
and one pleomorphic cancer. SCC, squamous cell carcinoma; ADC, adenocarcinoma.S36 Y.-S. Hong, M.-S. Roh, N.-Y. Kim, et al.
The results of this study demonstrate that the methyla-
tion of the p16INK4a gene is associated with tobacco smoking.
The association between promoter methylation and smok-
ing has been reported in other studies for various tumor sup-
pressor genes in NSCLC, including p16INK4a/CDKN2A and
RASSF1A (19-21). Tobacco smoke contains many carcino-
gens, including polyaromatic hydrocarbons, chromium, cad-
mium, plutonium, and nickel (22). In addition, tobacco
smoke is a mucosal irritant and thus induces inflammation,
which results in the generation of oxygen-free radicals. Fur-
thermore, smoking increases the activity of DNA methyl-
transferase (23), which drives the de novo hypermethylation
of susceptible loci (24). 
Clinicopathological characteristics, including age, sex,
tumor stage, and histologic type were not found to be corre-
lated with p16INK4a methylation. A previous investigation
(25) demonstrated that p16INK4a hypermethylation is a com-
mon and early event during lung carcinogenesis in general.
However, the small number of subjects involved in the pre-
sent study was not enough to draw a definite conclusion
regarding the interaction between the gene and other relat-
ed factors the testing of gene and related factor interactions,
which warrants further investigation in a larger study. 
Notably, in 22 cases in which p16INK4a hypermethylation
was observed in tumor tissues, only 4 (18.1%) cases were
found to have a hypermethylation status in normal tissues.
These results suggest that tumor tissues show more p16INK4a
hypermethylation than corresponding normal adjacent tissues.
In conclusion, this study shows that smoking can influence
the methylation level of the promoter region of p16INK4a, and
that this occurs in tumor tissues more frequently than in nor-
mal tissues. Other clinicopathological characteristics, includ-
ing age, sex, tumor stage, and histologic type, were not found
to be correlated with p16INK4a methylation. 
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